I think we're at a level (around here) that Berger will likely float 10 million shares and get another $100 million in the bank. Wouldn't be the worst thing.
I don't think Ponatinib partnership is forthcoming anytime soon.
I don't think an NDA filing is going to be a big "WOW" factor adding to the balance sheet.
Ariad needs to fund more trials in Ponatinib, and they need to fund the ALK trial.
And they need to keep the balance sheet large to continue attracting investors - a balance sheet of $75 million isn't a good look when you're burning $10-15 million a quarter.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.